Resolutions from the annual general meeting of Cyxone, 4 June 2020

Report this content

Today, on 4 June 2020, Cyxone AB (publ) held its annual general meeting (“AGM”) in Malmö. The AGM elected Bert Junno, chairman of the board of directors, as the chairman of the meeting. Oliver Cherek, associate at Fredersen Advokatbyrå, was the keeper of the minutes. A summary of the most important resolutions adopted follows below.


In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019.

Election of the board of directors, auditor and resolutions on remuneration etc. 

As members of the board of directors, re-election took place of Bert Junno, Theresa Comiskey Olsen, Saad Gilani and Mikael Lindstam. Bert Junno was re-elected as the chairman of the board of directors. It was resolved that remuneration will amount to SEK 300,000 to the chairman of the board and SEK 150,000 to every other board member. KPMG AB was re-elected as the company’s auditor, with Camilla Alm Andersson as the principal auditor. The board of directors and the CEO were discharged from liability for the financial year 2019.

Authorisation for the board of directors to resolve on new issues

The AGM resolved to authorize the board of directors to, on one or more occasions before the next AGM, with or without pre-emption rights for the shareholders, resolve on new issues of shares as well as issues of warrants and/or convertibles.

Malmö, 4 June 2020

Cyxone AB (publ)
The board of directors

Ola Skanung, CFO
Tel: +46 (0) 705 12 10 40
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,



Documents & Links